Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012 (Q86408281)

From Wikidata

Jump to navigation Jump to search

scientific article published on 13 March 2013

Language	Label	Description	Also known as
English	Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012	scientific article published on 13 March 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Report of the Cent Gardes HIV Vaccine Conference: The B-cell Response to HIV. Part 1: Broadly Neutralizing Antibodies Fondation Mérieux Conference Center, Veyrier du Lac, France, 5-7 November 2012 (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Valentina Picot

2

object named as

Valentina Picot

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

4

object named as

Gary J Nabel

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

author name string

Marc P Girard

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Christophe Longuet

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

publication date

13 March 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

31

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

29

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

2979-2983

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Rational antibody-based HIV-1 vaccine design: current approaches and future directions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Broad neutralization coverage of HIV by multiple highly potent antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Rational modifications of HIV-1 envelope glycoproteins for immunogen design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Prospects of HIV Env modification as an approach to HIV vaccine design

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Antibody-based protection against HIV infection by vectored immunoprophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Frequency and genetic characterization of V(DD)J recombinants in the human peripheral blood antibody repertoire.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Antibodies to a superantigenic glycoprotein 120 epitope as the basis for developing an HIV vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Pemphigoid diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

The development of CD4 binding site antibodies during HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Crystal Structure of the Neutralizing Llama VHH D7 and Its Mode of HIV-1 gp120 Interaction

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Elicitation of structure-specific antibodies by epitope scaffolds

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

HIV-1 envelope trimer elicits more potent neutralizing antibody responses than monomeric gp120.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Nonviral delivery of self-amplifying RNA vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Report of the Cent Gardes HIV Vaccine Conference: The B-cell response to HIV. Part 2: Non-neutralizing antibodies: Fondation Mérieux Conference Center, Veyrier du Lac, France 5-7 November 2012.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Neutralizing antibodies and control of HIV: moves and countermoves.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.068

7 January 2021

Identifiers

10.1016/J.VACCINE.2013.02.068

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23499518%20AND%20SRC:MED&resulttype=core&format=json

26 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q86408281&oldid=1369037274"